Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04527887 · ClinicalTrials.gov registry record · Phase 4
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
A Phase 4 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
NCT04527887 is a Phase 4 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 54 participants.
The verdict
NCT04527887, a Phase 4 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
Study Summary
This prospective, single-center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of Intracanalicular dexamethasone Insert (IDI) on ameliorating the signs and symptoms of dry eye disease.
Interventions
- DRUG Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)
- OTHER ProLong™ collagen plugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-09-04 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04527887
The ClinicalTrials.gov registry entry for NCT04527887 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg) is the first listed.
NCT04527887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04527887 about?
NCT04527887 is a clinical study titled "Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)". This prospective, single-center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of Intracanalicular dexamethasone Insert (IDI) on ameliorating the signs and symptoms of dry eye disease.
What is the current status of trial NCT04527887?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2020-09-04. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04527887?
The interventions under investigation include: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg) (DRUG), ProLong™ collagen plugs (OTHER).
Who is sponsoring clinical trial NCT04527887?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.